RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells

Biochemical and Biophysical Research Communications

Volumn 446, Issue 4, 2014, Pages 1204-1210

  Wang, Houcai ^a   Yu, Jing ^a   Zhang, Lixia ^a   Xiong, Yuanyuan ^a   Chen, Shuying ^a   Xing, Haiyan ^a   Tian, Zheng ^a   Tang, Kejing ^a   Wei, Hui ^a   Rao, Qing ^a   Wang, Min ^a   Wang, Jianxiang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Apoptosis; Cell cycle arrest; Imatinib; Leukemia; Proliferation; RPS27a

Indexed keywords

APOPTOSIS; CELL CYCLE ARREST; IMATINIB; LEUKEMIA; PROLIFERATION; RPS27A;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; RIBOSOMAL PROTEINS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84899483452     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.03.086     Document Type: Article

References (28)

1. M.W. Deininger, J.M. Goldman, and J.V. Melo The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
2. M. Sattler, and J.D. Griffin Molecular mechanisms of transformation by the BCR-ABL oncogene Semin. Hematol. 40 2003 4 10
3. M.J. Mauro, M.E. O'Dwyer, and B.J. Druker ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy Cancer Chemother. Pharmacol. 48 Suppl. 1 2001 S77 S78
4. B.J. Druker, M. Talpaz, and D.J. Resta et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
5. H.M. Kantarjian, J.E. Cortes, and S. O'Brien et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses Blood 101 2003 97 100
6. J. Moravcova, V. Zmekova, and H. Klamova et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase Leuk. Res. 28 2004 415 419
7. B. Calabretta, and D. Perrotti The biology of CML blast crisis Blood 103 2004 4010 4022
8. D. Perrotti, C. Jamieson, and J. Goldman et al. Chronic myeloid leukemia: mechanisms of blastic transformation J. Clin. Invest. 120 2010 2254 2264
9. T. Lahaye, B. Riehm, and U. Berger et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 103 2005 1659 1669
10. C.L. Sawyers, A. Hochhaus, and E. Feldman et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 2002 3530 3539
11. J. Qi, H. Peng, and Z.L. Gu et al. Establishment of an imatinib resistant cell line K562/G01 and its characterization Zhonghua Xue Ye Xue Za Zhi 25 2004 337 341
12. M.E. Gorre, M. Mohammed, and K. Ellwood et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
13. S. Branford, Z. Rudzki, and S. Walsh et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 2003 276 283
14. K.L. Redman, and M. Rechsteiner Identification of the long ubiquitin extension as ribosomal protein S27a Nature 338 1989 438 440
15. N. Shabek, and A. Ciechanover Degradation of ubiquitin: the fate of the cellular reaper Cell Cycle 9 2010 523 530
16. D. Komander, M.J. Clague, and S. Urbe Breaking the chains: structure and function of the deubiquitinases Nat. Rev. Mol. Cell Biol. 10 2009 550 563
17. S.M. Adams, M.G. Sharp, and R.A. Walker et al. Differential expression of translation-associated genes in benign and malignant human breast tumours Br. J. Cancer 65 1992 65 71
18. J.M. Wong, K. Mafune, and H. Yow et al. Ubiquitin-ribosomal protein S27a gene overexpressed in human colorectal carcinoma is an early growth response gene Cancer Res. 53 1993 1916 1920
19. H. Kanayama, K. Tanaka, and M. Aki et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells Cancer Res. 51 1991 6677 6685
20. X.X. Sun, T. DeVine, and K.B. Challagundla et al. Interplay between ribosomal protein S27a and MDM2 protein in p53 activation in response to ribosomal stress J. Biol. Chem. 286 2009 22730 22741
21. J.R. Warner, and K.B. McIntosh How common are extraribosomal functions of ribosomal proteins? Mol. Cell 34 2009 3 11
22. I.G. Wool Extraribosomal functions of ribosomal proteins Trends Biochem. Sci. 21 1996 164 165
23. Y. Kano, M. Akutsu, and S. Tsunoda et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood 97 2001 1999 2007
24. D. Bixby, and M. Talpaz Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia Leukemia 25 2011 7 22
25. D. Cilloni, F. Messa, and F. Arruga et al the NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance Leukemia 20 2006 61 67
26. K. Kawauchi, T. Ogasawara, and M. Yasuyama et al the PI3K/Akt pathway as a target in the treatment of hematologic malignancies Anticancer Agents Med. Chem. 9 2009 550 559
27. L.B. Chen Mitochondrial membrane potential in living cells Annu. Rev. Cell Biol. 4 1988 155 181
28. P. Sancho, E. Galeano, and M.C. Estan et al. Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562 Exp. Biol. Med. 237 2012 933 942